US FDA advisory panel backs Salix's Xifaxan for hepatic encephalopathy
This article was originally published in Scrip
Executive Summary
Salix Pharmaceuticals has won a strong endorsement from the US FDA's advisory committee on gastrointestinal drugs for approval of a new indication for its semi-synthetic antibiotic Xifaxan (rifaximin).